News

Read the latest news and explore the latest media coverage about Jeeva

The Need To Increase Diversity In Clinical Trials

The Need To Increase Diversity In Clinical Trials

By Lilly Skok Bunch – Executive Director of Greater Gift in Winston-Salem Jul 7, 2022 The clinical research system’s mistakes stem from historical events that adversely impacted racial and ethnic minorities, such as the Tuskegee experiments.

Digital Transformation in the Life Sciences Accelerates

Digital Transformation in the Life Sciences Accelerates

Information technology, underpinned by advancements in Cloud computing, is no longer the understudy to the scientific, R&D lead. Biotech, pharma, healthcare and medtech organizations need to understand that building a fully integrated, enterprise level digital ecosystem

TIM KAINE

Highlights of Virginia Small Business Success Stories

WASHINGTON, D.C. May 2, 2022 Today, U.S. Senator Tim Kaine is highlighting small business success stories from across the Commonwealth in honor of National Small Business Week (May 1-7), a week dedicated to supporting small businesses.

Global Disruption: Decentralizing Clinical Trials for Diversity

Global Disruption: Decentralizing Clinical Trials for Diversity

JoTo PR Disruptors’ signs Jeeva Informatics, a human-centric Software as a Service (SaaS) company that is working to revolutionize the clinical trials space at scale. Diversity, more enrollment, less dropouts and more global participation are some

Decentralizing Clinical Trials Through Disruption

Decentralizing Clinical Trials Through Disruption

Clinical trials are expensive, take significant time, and can run into any number of challenges and delays. The average drug study will see a 30% patient dropout rate. What is needed, according to Virginia-based Jeeva Informatics,

Diversifying Clinical Trials

Diversifying Clinical Trials

Over the past two years, the testing of new medical devices, drugs and vaccines has increasingly been performed outside large medical centers. Faster enrollment, fewer dropouts and global diversification of trial participants are some of the